369 related articles for article (PubMed ID: 34875824)
1. Association Between Low Muscle Mass and Non-alcoholic Fatty Liver Disease Diagnosed Using Ultrasonography, Magnetic Resonance Imaging Derived Proton Density Fat Fraction, and Comprehensive NAFLD Score in Korea.
Lee HJ; Chang JS; Ahn JH; Kim MY; Park KS; Ahn YS; Koh SB
J Prev Med Public Health; 2021 Nov; 54(6):412-421. PubMed ID: 34875824
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
Jeon SK; Lee JM; Joo I; Park SJ
Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
[TBL] [Abstract][Full Text] [Related]
4. Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort.
Choe HJ; Lee H; Lee D; Kwak SH; Koo BK
J Cachexia Sarcopenia Muscle; 2023 Feb; 14(1):260-269. PubMed ID: 36403577
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Ajmera V; Park CC; Caussy C; Singh S; Hernandez C; Bettencourt R; Hooker J; Sy E; Behling C; Xu R; Middleton MS; Valasek MA; Faulkner C; Rizo E; Richards L; Sirlin CB; Loomba R
Gastroenterology; 2018 Aug; 155(2):307-310.e2. PubMed ID: 29660324
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.
Han A; Zhang YN; Boehringer AS; Montes V; Andre MP; Erdman JW; Loomba R; Valasek MA; Sirlin CB; O'Brien WD
Radiology; 2020 Apr; 295(1):106-113. PubMed ID: 32013792
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
8. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
[TBL] [Abstract][Full Text] [Related]
9. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
Lemoine M; Assoumou L; Girard PM; Valantin MA; Katlama C; De Wit S; Campa P; Rougier H; Meynard JL; Necsoi C; Huefner AD; Van Luzen J; Schulze Zur Wiesch J; Bastard JP; Fellahi S; Mauss S; Stankov MV; Baumgarten A; Post G; Serfaty L; Ratziu V; Menu Y; Schlue J; Bedossa P; Capeau J; Costagliola D; Behrens G; Ingiliz P;
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):713-722.e3. PubMed ID: 35436624
[TBL] [Abstract][Full Text] [Related]
10. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study.
Eroğlu İ; Iremli BG; Erkoc A; Idilman IS; Yuce D; Kutukcu EC; Akata D; Erbas T
J Clin Densitom; 2024; 27(2):101479. PubMed ID: 38447349
[TBL] [Abstract][Full Text] [Related]
12. Muscle Mass Is Linked to Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease.
Yodoshi T; Orkin S; Arce Clachar AC; Bramlage K; Sun Q; Fei L; Beck AF; Xanthakos SA; Trout AT; Mouzaki M
J Pediatr; 2020 Aug; 223():93-99.e2. PubMed ID: 32711755
[TBL] [Abstract][Full Text] [Related]
13. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
[TBL] [Abstract][Full Text] [Related]
14. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
[TBL] [Abstract][Full Text] [Related]
17. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
[TBL] [Abstract][Full Text] [Related]
18. Utility of MR proton density fat fraction and its correlation with ultrasonography and biochemical markers in nonalcoholic fatty liver disease in overweight adolescents.
Netaji A; Jain V; Gupta AK; Kumar U; Jana M
J Pediatr Endocrinol Metab; 2020 Apr; 33(4):473-479. PubMed ID: 32146441
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
20. Correlation between magnetic resonance imaging proton density fat fraction (MRI-PDFF) and liver biopsy to assess hepatic steatosis in obesity.
Wibulpolprasert P; Subpinyo B; Chirnaksorn S; Shantavasinkul PC; Putadechakum S; Phongkitkarun S; Sritara C; Angkathunyakul N; Sumritpradit P
Sci Rep; 2024 Mar; 14(1):6895. PubMed ID: 38519637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
